{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:17:16Z","timestamp":1774628236223,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,27]]},"DOI":"10.7759\/cureus.105980","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:41:45Z","timestamp":1774626105000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Topical Clobetasol Propionate 0.05% Ointment Versus Topical Methotrexate 1% Gel in Limited Plaque Psoriasis: A Prospective Open-Label Study"],"prefix":"10.7759","author":[{"given":"Radhika","family":"Thakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh P","family":"Asati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapila","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishesh","family":"Budhwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.239","article-title":"National Psoriasis Foundation clinical consensus on disease severity","volume":"143","author":"Pariser DM","year":"2007","unstructured":"Pariser DM, Bagel J, Gelfand JM, et al.. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007, 143:239-42. 10.1001\/archderm.143.2.239","journal-title":"Arch Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00192.x","article-title":"The prevalence of psoriasis in the world","volume":"15","author":"Raychaudhuri SP","year":"2001","unstructured":"Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001, 15:16-7. 10.1046\/j.1468-3083.2001.00192.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","article-title":"Psoriasis in the tropics: an epidemiological survey","volume":"41","author":"Okhandiar RP","year":"1963","unstructured":"Okhandiar RP, Banerjee BN. Psoriasis in the tropics: an epidemiological survey. J Indian Med Assoc. 1963, 41:550-6.","journal-title":"J Indian Med Assoc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.193906","article-title":"Psoriasis: epidemiology, clinical features, co-morbidities, and clinical scoring","volume":"7","author":"Dogra S","year":"2016","unstructured":"Dogra S, Mahajan R. Psoriasis: epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016, 7:471-80. 10.4103\/2229-5178.193906","journal-title":"Indian Dermatol Online J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes MA","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014, 32:227-55. 10.1146\/annurev-immunol-032713-120225","journal-title":"Annu Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.193908","article-title":"General measures and quality of life issues in psoriasis","volume":"7","author":"Sarkar R","year":"2016","unstructured":"Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016, 7:481-8. 10.4103\/2229-5178.193908","journal-title":"Indian Dermatol Online J"},{"key":"ref7","unstructured":"Psoriasis. quality of life. (2024). Accessed: March 1, 2026: https:\/\/www.almirall.com\/your-health\/your-skin\/skin-conditions\/psoriasis\/quality-of-life."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114\/pg.2015.53376","article-title":"Relationship between psoriasis and non-alcoholic fatty liver disease","volume":"11","author":"Narayanasamy K","year":"2016","unstructured":"Narayanasamy K, Sanmarkan AD, Rajendran K, Annasamy C, Ramalingam S. Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol. 2016, 11:263-9. 10.5114\/pg.2015.53376","journal-title":"Prz Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.183638","article-title":"Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: a hospital-based cross-sectional study","volume":"82","author":"Kothiwala SK","year":"2016","unstructured":"Kothiwala SK, Khanna N, Tandon N, Naik N, Sharma VK, Sharma S, Sreenivas V. Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: a hospital-based cross-sectional study. Indian J Dermatol Venereol Leprol. 2016, 82:510-8. 10.4103\/0378-6323.183638","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref10","unstructured":"Can you use clobetasol propionate for psoriasis?. (2024). Accessed. March 1, 2026: https:\/\/www.healthline.com\/health\/psoriasis\/clobetasol-propionate-for-psoriasis."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.142483","article-title":"Side-effects of topical steroids: a long overdue revisit","volume":"5","author":"Coondoo A","year":"2014","unstructured":"Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014, 5:416-25. 10.4103\/2229-5178.142483","journal-title":"Indian Dermatol Online J"},{"key":"ref12","unstructured":"Side effects of clobetasol. (2022). Accessed. March 1, 2026: https:\/\/www.nhs.uk\/medicines\/clobetasol\/side-effects-of-clobetasol\/."},{"key":"ref13","unstructured":"Clobetasol topical side effects. (2025). Accessed. March 1, 2026: https:\/\/www.drugs.com\/sfx\/clobetasol-topical-side-effects.html."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge UR","year":"2006","unstructured":"Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006, 54:1-18. 10.1016\/j.jaad.2005.01.010","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02911.x","article-title":"The treatment of psoriasis vulgaris: 1% topical methotrexate gel","volume":"45","author":"Eskicirak B","year":"2006","unstructured":"Eskicirak B, Zemheri E, Cerkezoglu A. The treatment of psoriasis vulgaris: 1% topical methotrexate gel. Int J Dermatol. 2006, 45:965-9. 10.1111\/j.1365-4632.2006.02911.x","journal-title":"Int J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S380218","article-title":"The anti-psoriatic efficacy and safety profile of topical and intralesional methotrexate: a literature review","volume":"15","author":"Chaiyabutr C","year":"2022","unstructured":"Chaiyabutr C, Punnakitikashem P, Silpa-Archa N, Wongpraprarut C, Chularojanamontri L. The anti-psoriatic efficacy and safety profile of topical and intralesional methotrexate: a literature review. Clin Cosmet Investig Dermatol. 2022, 15:2253-74. 10.2147\/CCID.S380218","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.32007\/jfacmedbagdad.5211047","article-title":"Topical methotrexate for treatment of psoriasis: formulation and clinical implications","volume":"52","author":"Jabur MS","year":"2010","unstructured":"Jabur MS, Ghazal MRI, Al-Hamamy HR. Topical methotrexate for treatment of psoriasis: formulation and clinical implications. J Fac Med Baghdad. 2010, 52:32-6. 10.32007\/jfacmedbagdad.5211047","journal-title":"J Fac Med Baghdad"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.32709","article-title":"Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies","volume":"73","author":"Lakshmi PK","year":"2007","unstructured":"Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol. 2007, 73:157-61. 10.4103\/0378-6323.32709","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000250839","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson T","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978, 157:238-44. 10.1159\/000250839","journal-title":"Dermatologica"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley RG","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015, 26:23-31. 10.3109\/09546634.2013.865009","journal-title":"J Dermatolog Treat"},{"key":"ref21","article-title":"Factor analysis of the Beer Sheva Psoriasis Severity Score (BPSS)","volume":"10","author":"Cohen AD","year":"2008","unstructured":"Cohen AD, Van-Dijk D, Naggan L, Vardy DA. Factor analysis of the Beer Sheva Psoriasis Severity Score (BPSS). Isr Med Assoc J. 2008, 10:419-23.","journal-title":"Isr Med Assoc J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt J","year":"2005","unstructured":"Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005, 210:194-9. 10.1159\/000083509","journal-title":"Dermatology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"Puzenat E","year":"2010","unstructured":"Puzenat E, Bronsard V, Prey S, et al.. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010, 24:10-6. 10.1111\/j.1468-3083.2009.03562.x","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/472513-comparative-efficacy-and-safety-of-topical-clobetasol-propionate-005-ointment-versus-topical-methotrexate-1-gel-in-limited-plaque-psoriasis-a-prospective-open-label-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:41:48Z","timestamp":1774626108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/472513-comparative-efficacy-and-safety-of-topical-clobetasol-propionate-005-ointment-versus-topical-methotrexate-1-gel-in-limited-plaque-psoriasis-a-prospective-open-label-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.105980","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}